ZAIVALIFESCIENCES
Epimeth pharmaceutical pack by Zaiva Lifesciences

Neurology & Neuropathic Pain

Epimeth

Epalrestat · 150 mg

Epalrestat 150 mg extended-release therapy targeting the polyol pathway in diabetic peripheral neuropathy.

BrandEpimeth
CompositionEpalrestat
Strength150 mg
Dosage formTablet

Overview

Diabetic peripheral neuropathy where epalrestat is clinically appropriate.

  • Inhibits aldose reductase in the polyol pathway.
  • Mechanistic rationale is reduction of sorbitol accumulation associated with chronic hyperglycaemia.
  • Evidence and regulatory status vary internationally; local approved information should guide use.

Composition & dosage

Composition: Epalrestat · 150 mg

Dosage form: Tablet

Dosage: As prescribed by the doctor.

How it works

Aldose reductase inhibition reduces conversion of glucose to sorbitol in the polyol pathway; intended to reduce hyperglycemia-related metabolic nerve injury.

  1. Aldose reductase inhibition reduces conversion of glucose to sorbitol in the polyol pathway
  2. intended to reduce hyperglycemia-related metabolic nerve injury.

Epalrestat targets the polyol pathway through aldose-reductase inhibition. Long-term comparative evidence supports effects on diabetic neuropathy measures in selected patients.

Safety information

  • Monitor adverse effects and laboratory parameters according to local prescribing information.
  • Do not substitute this portal for local approved labeling.
  • Diabetes control and comprehensive neuropathy management remain essential.

Review the current approved prescribing information, contraindications, interactions, organ-function considerations, pregnancy/lactation advice and patient-specific risks before prescribing.

Evidence context

Epalrestat targets the polyol pathway through aldose-reductase inhibition. Long-term comparative evidence supports effects on diabetic neuropathy measures in selected patients.

Evidence is strongest in diabetic neuropathy populations studied in Asia/Japan and should not be generalized to all neuropathic pain.